Currently, immune checkpoint blocking agents, including antibodies that inhibit PD-1, PD-L1, and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), are being successfully investigated and applied to the patients with ccRCC. Here, CD274 is linked to nonpapillary renal cell carcinoma.